HUP0303976A2 - Kombinációs terápia anti-EGFR-ellenanyagok és hormonantagonisták együttes alkalmazásával - Google Patents
Kombinációs terápia anti-EGFR-ellenanyagok és hormonantagonisták együttes alkalmazásávalInfo
- Publication number
- HUP0303976A2 HUP0303976A2 HU0303976A HUP0303976A HUP0303976A2 HU P0303976 A2 HUP0303976 A2 HU P0303976A2 HU 0303976 A HU0303976 A HU 0303976A HU P0303976 A HUP0303976 A HU P0303976A HU P0303976 A2 HUP0303976 A2 HU P0303976A2
- Authority
- HU
- Hungary
- Prior art keywords
- hormone antagonists
- combination therapy
- subject
- well
- egfr antibodies
- Prior art date
Links
- 239000003667 hormone antagonist Substances 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 239000002254 cytotoxic agent Substances 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 208000023958 prostate neoplasm Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A találmány tárgyát tumorok és tumormetasztázisok, elsősorban emlő- ésprosztatatumorok kezelésére alkalmas kombinációs terápia képezi, amelyszerint EGFR (Herl ) ellen irányuló ellenanyagokat, valaminthormonantagonistákat adnak be, adott esetben, citotoxikus és/vagykemoterápiás ágenssel együtt. Az eljárás alkalmazása, valamint ahatóanyagokat tartalmazó gyógyászati készítmények szinergista módonképesek fokozni az egyes terápiás hatóanyagok tumorsejt-proliferációtgátló hatását, hatásosabb kezelést eredményezve, mint amilyen az egyeskomponensek külön-külön történő beadásával elérhető. A találmánytárgyát képezik az ellenanyagokat és a hormonantagonistákat tartalmazógyógyászati készítmények és készletek, továbbá ezek alkalmazásaigyógyszerek vagy gyógyszerösszetételek előállítására. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01111049 | 2001-05-08 | ||
PCT/EP2002/004404 WO2002089842A1 (en) | 2001-05-08 | 2002-04-22 | Combination therapy using anti-egfr antibodies and anti-hormonal agents |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0303976A2 true HUP0303976A2 (hu) | 2004-03-01 |
HUP0303976A3 HUP0303976A3 (en) | 2006-11-28 |
Family
ID=8177348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0303976A HUP0303976A3 (en) | 2001-05-08 | 2002-04-22 | Combination therapy using anti-egfr antibodies and hormone antagonists |
Country Status (16)
Country | Link |
---|---|
US (2) | US20040131611A1 (hu) |
EP (1) | EP1385546A1 (hu) |
JP (1) | JP2004528368A (hu) |
KR (1) | KR20040029975A (hu) |
CN (1) | CN1507355A (hu) |
AU (1) | AU2002315306B2 (hu) |
BR (1) | BR0209147A (hu) |
CA (1) | CA2449166A1 (hu) |
CZ (1) | CZ20033226A3 (hu) |
HU (1) | HUP0303976A3 (hu) |
MX (1) | MXPA03010121A (hu) |
PL (1) | PL363322A1 (hu) |
RU (1) | RU2003134180A (hu) |
SK (1) | SK14632003A3 (hu) |
WO (1) | WO2002089842A1 (hu) |
ZA (1) | ZA200309437B (hu) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE446317T1 (de) | 2001-05-11 | 2009-11-15 | Ludwig Inst For Cancer Res Ltd | Spezifische bindungsproteine und ihre verwendung |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
ATE477280T1 (de) * | 2001-06-28 | 2010-08-15 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
JP2006512895A (ja) * | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
EP1578801A2 (en) * | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
MXPA05010575A (es) * | 2003-04-04 | 2006-03-09 | Univ Lausanne | Peptacuerpo para el tratamiento del cancer. |
AP2006003620A0 (en) * | 2003-10-15 | 2006-06-30 | Osi Pharm Inc | Imidazopyrazine tyroshine kinase inhibitors |
MXPA06011423A (es) | 2004-04-02 | 2007-01-23 | Osi Pharm Inc | Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico. |
EP1758601A1 (en) | 2004-06-03 | 2007-03-07 | F.Hoffmann-La Roche Ag | Treatment with cisplatin and an egfr-inhibitor |
BRPI0512235A (pt) * | 2004-06-18 | 2008-02-19 | Ambrx Inc | polipeptìdeos ligadores de antìgenos e seus usos |
KR20170134771A (ko) | 2005-01-21 | 2017-12-06 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
NZ556561A (en) * | 2005-02-02 | 2011-08-26 | Macrogenics West Inc | Adam-9 modulators |
KR101253576B1 (ko) | 2005-02-23 | 2013-04-11 | 제넨테크, 인크. | Her 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장 |
DK1896077T3 (da) | 2005-06-29 | 2012-12-03 | Hills Pet Nutrition Inc | Fremgangsmåder og sammensætninger til forebyggelse og behandling af inflammatoriske sygdomme |
US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
PT1937244T (pt) | 2005-09-30 | 2018-11-07 | Io Therapeutics Llc | Tratamento do cancro com agonistas específicos de rxr |
CA2632866A1 (en) * | 2005-12-01 | 2007-06-07 | Domantis Limited | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
CA2651487A1 (en) * | 2006-05-16 | 2007-11-29 | Vitae Pharmaceuticals, Inc. | Methods for treating chemotherapy and radiation therapy side effects |
CU23612A1 (es) * | 2006-09-29 | 2010-12-08 | Centro Inmunologia Molecular | Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico |
JP5276017B2 (ja) | 2007-01-25 | 2013-08-28 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Egfr変異体仲介性疾患の治療における抗egfr抗体の使用 |
EP2899541A1 (en) | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
CN101688229B (zh) | 2007-03-15 | 2013-06-12 | 路德维格癌症研究所 | 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途 |
ATE540676T1 (de) * | 2007-04-13 | 2012-01-15 | Rikshospitalet Radiumhospitalet Hf | Egfr-inhibitoren zur behandlung und diagnose von metastasierendem prostatakrebs |
EA200901301A1 (ru) * | 2007-06-06 | 2010-06-30 | Домантис Лимитед | Полипептиды, вариабельные домены антител и антагонисты |
US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
PL2171090T3 (pl) | 2007-06-08 | 2013-09-30 | Genentech Inc | Markery ekspresji genów odporności guza na leczenie hamujące HER2 |
CN101896503B (zh) | 2007-08-14 | 2018-05-22 | 路德维格癌症研究所有限公司 | 靶向egf受体的单克隆抗体175及其衍生物和用途 |
EP2250173A1 (en) * | 2008-01-18 | 2010-11-17 | OSI Pharmaceuticals, Inc. | Imidazopyrazinol derivatives for the treatment of cancers |
JP2011520970A (ja) * | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換されたイミダゾピラジン類およびイミダゾトリアジン類 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
US20120064072A1 (en) | 2009-03-18 | 2012-03-15 | Maryland Franklin | Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor |
AR075896A1 (es) | 2009-03-20 | 2011-05-04 | Genentech Inc | Anticuerpos anti-her (factor de crecimiento epidermico) |
CA2752826A1 (en) | 2009-04-20 | 2010-10-28 | OSI Pharmaceuticals, LLC | Preparation of c-pyrazine-methylamines |
JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 副腎皮質癌を治療するためのosi−906の使用 |
SG10201507044PA (en) | 2009-05-29 | 2015-10-29 | Hoffmann La Roche | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
JP5981853B2 (ja) | 2010-02-18 | 2016-08-31 | ジェネンテック, インコーポレイテッド | ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用 |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
EP2643353A1 (en) | 2010-11-24 | 2013-10-02 | Novartis AG | Multispecific molecules |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
KR20140057326A (ko) | 2011-08-17 | 2014-05-12 | 제넨테크, 인크. | 뉴레귤린 항체 및 그의 용도 |
US9327023B2 (en) | 2011-10-25 | 2016-05-03 | The Regents Of The University Of Michigan | HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells |
CN106987620A (zh) | 2011-11-30 | 2017-07-28 | 霍夫曼-拉罗奇有限公司 | 癌症中的erbb3突变 |
EP2788500A1 (en) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Identification of non-responders to her2 inhibitors |
AU2012352149B2 (en) | 2011-12-13 | 2017-06-01 | Io Therapeutics, Inc. | Autoimmune disorder treatment using RXR agonists |
WO2013148315A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
KR102291355B1 (ko) | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 |
EP3368080B8 (en) | 2015-10-31 | 2023-04-26 | IO Therapeutics, Inc. | Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones |
CN114470218A (zh) | 2016-03-10 | 2022-05-13 | Io治疗公司 | 用rxr激动剂与甲状腺激素的组合的自身免疫疾病的治疗 |
MX2018010863A (es) | 2016-03-10 | 2019-01-10 | Io Therapeutics Inc | Tratamiento contra trastornos musculares con combinaciones de agonistas rxr y hormonas tiroideas. |
WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
EP3684348A4 (en) | 2017-09-20 | 2021-08-18 | IO Therapeutics, Inc. | TREATMENT OF DISEASE WITH SELECTIVE RXR AGONIST ESTERS |
US10966950B2 (en) | 2019-06-11 | 2021-04-06 | Io Therapeutics, Inc. | Use of an RXR agonist in treating HER2+ cancers |
CN113207799B (zh) * | 2021-03-19 | 2022-03-15 | 中山大学 | 一种二型糖尿病小鼠快速心衰模型的构建方法 |
WO2023108012A1 (en) | 2021-12-07 | 2023-06-15 | Io Therapeutics, Inc. | Use of an rxr agonist and taxanes in treating her2+ cancers |
CN116333117B (zh) * | 2021-12-16 | 2024-04-26 | 徕特康(苏州)生物制药有限公司 | 抗表皮生长因子受体抗体及其制备方法和用途 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3854306B2 (ja) * | 1991-03-06 | 2006-12-06 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | ヒト化及びキメラモノクローナル抗体 |
WO1999008668A2 (en) * | 1997-08-15 | 1999-02-25 | Cephalon, Inc. | Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer |
WO1999059636A1 (fr) * | 1998-05-20 | 1999-11-25 | Kyowa Hakko Kogyo Co., Ltd. | Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf) |
IL146480A0 (en) * | 1999-05-14 | 2002-07-25 | Imclone Systems Inc | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
TR200200472T2 (tr) * | 1999-08-27 | 2002-06-21 | Genentech, Inc. | Anti-Erb B2 antikorları ile tedavi için dozajlar |
CA2422881A1 (en) * | 2000-10-13 | 2002-04-18 | Uab Research Foundation | Human anti-epidermal growth factor receptor single-chain antibodies |
-
2002
- 2002-04-22 RU RU2003134180/15A patent/RU2003134180A/ru not_active Application Discontinuation
- 2002-04-22 JP JP2002586974A patent/JP2004528368A/ja not_active Withdrawn
- 2002-04-22 WO PCT/EP2002/004404 patent/WO2002089842A1/en active IP Right Grant
- 2002-04-22 BR BR0209147-0A patent/BR0209147A/pt not_active IP Right Cessation
- 2002-04-22 HU HU0303976A patent/HUP0303976A3/hu unknown
- 2002-04-22 PL PL02363322A patent/PL363322A1/xx unknown
- 2002-04-22 EP EP02740492A patent/EP1385546A1/en not_active Withdrawn
- 2002-04-22 AU AU2002315306A patent/AU2002315306B2/en not_active Ceased
- 2002-04-22 KR KR10-2003-7014552A patent/KR20040029975A/ko not_active Application Discontinuation
- 2002-04-22 MX MXPA03010121A patent/MXPA03010121A/es unknown
- 2002-04-22 CZ CZ20033226A patent/CZ20033226A3/cs unknown
- 2002-04-22 CN CNA028095146A patent/CN1507355A/zh active Pending
- 2002-04-22 SK SK1463-2003A patent/SK14632003A3/sk not_active Application Discontinuation
- 2002-04-22 CA CA002449166A patent/CA2449166A1/en not_active Abandoned
- 2002-04-22 US US10/476,478 patent/US20040131611A1/en not_active Abandoned
-
2003
- 2003-12-04 ZA ZA200309437A patent/ZA200309437B/en unknown
-
2007
- 2007-04-26 US US11/789,883 patent/US20070202101A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN1507355A (zh) | 2004-06-23 |
WO2002089842A1 (en) | 2002-11-14 |
CZ20033226A3 (en) | 2004-07-14 |
US20040131611A1 (en) | 2004-07-08 |
EP1385546A1 (en) | 2004-02-04 |
ZA200309437B (en) | 2005-03-04 |
HUP0303976A3 (en) | 2006-11-28 |
PL363322A1 (en) | 2004-11-15 |
US20070202101A1 (en) | 2007-08-30 |
BR0209147A (pt) | 2004-06-08 |
KR20040029975A (ko) | 2004-04-08 |
JP2004528368A (ja) | 2004-09-16 |
CA2449166A1 (en) | 2002-11-14 |
MXPA03010121A (es) | 2004-03-10 |
AU2002315306B2 (en) | 2007-05-17 |
SK14632003A3 (sk) | 2004-03-02 |
RU2003134180A (ru) | 2005-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0303976A2 (hu) | Kombinációs terápia anti-EGFR-ellenanyagok és hormonantagonisták együttes alkalmazásával | |
SG166775A1 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
HUP0303927A2 (hu) | Anti-angiogén ágensek és TNF-alfa alkalmazása kombinációs kezelésre | |
HK1071310A1 (en) | Combination therapy for the treatment of cancer | |
Petrella et al. | Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells | |
TW200744636A (en) | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | |
EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
MY124853A (en) | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives. | |
BR0316050A (pt) | Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit | |
HUP0400203A2 (hu) | Epotilon analógok és kemoterápiás szerek kombinációja proliferatív betegségek kezelésére alkalmas gyógyszerkészítmény előállítására | |
IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
CA2464758A1 (en) | Combination therapy comprising zd6474 and a taxane | |
WO2004096159A3 (en) | Saposin c-dops: a novel anti-tumor agent | |
MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
BRPI0508982A (pt) | uso de azd2171 ou de um sal deste farmaceuticamente aceitável excluindo um sal de maleato de azd2171, composição farmacêutica, kit, método para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, e, uso de sal de maleato de azd2171 e 5 - fu e cpt - 11 | |
TW200608959A (en) | Treatment with oxaliplatin and an egfr-inhibitor | |
MXPA04001912A (es) | Aminobenzofenonas novedosas. | |
RU2010119922A (ru) | Усовершенствованное противоопухолевое лечение | |
ATE330600T1 (de) | Kombinationspräparat zur krebstherapie | |
RU2013149175A (ru) | Лекарственное средство, содержащее лектины омелы, для лечения злокачественной меланомы | |
ATE385798T1 (de) | Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen | |
WO2003061571A3 (en) | Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein | |
ES2211374T1 (es) | Dosificacion metronomica de taxanos para inhibir el crecimiento tumoral. | |
MD3381G2 (ro) | Metodă de tratament al parotiditei cronice la copii |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |